PheWAS associations assessed by conventional MR IVW and MR Egger analysis
| Disease outcomes | MR IVW | MR Egger | |||||
| OR (95% CI) | P effect | Power* | OR (95% CI) | P effect | P pleiotropy | Power* | |
| Gout | 4.88 (3.91 to 6.09) | 3.55e-15 | 1.00 | 4.58 (2.72 to 7.72) | 1.76e-06 | 0.73 | 1.00 |
| Inflammatory polyarthropathies† | 1.22 (1.11 to 1.34) | 1.10e-04 | 0.99 | 1.15 (1.01 to 1.31) | 0.03 | 0.23 | 0.83 |
| Essential hypertension | 1.08 (1.03 to 1.14) | 5.07e-03 | 0.82 | 0.93 (0.83 to 1.05) | 0.23 | 1.13e-03 | 0.73 |
| Hypertensive disease | 1.08 (1.03 to 1.14) | 4.23e-03 | 0.82 | 0.93 (0.83 to 1.05) | 0.24 | 1.19e-03 | 0.73 |
| Myocardial infarction | 1.16 (1.03 to 1.30) | 0.02 | 0.70 | 1.03 (0.84 to 1.27) | 0.75 | 0.13 | 0.08 |
| Coeliac disease | 1.41 (1.05 to 1.89) | 0.02 | 0.72 | 1.31 (0.68 to 2.54) | 0.41 | 0.75 | 0.48 |
| Disorders of metabolism† | 1.07 (1.01 to 1.14) | 0.03 | 0.52 | 1.01 (0.91 to 1.14) | 0.80 | 0.18 | 0.06 |
| Coronary atherosclerosis | 1.07 (0.99 to 1.15) | 0.08 | 0.41 | 0.99 (0.85 to 1.17) | 0.95 | 0.20 | 0.06 |
| Ischaemic heart disease | 1.07 (0.99 to 1.15) | 0.09 | 0.41 | 0.99 (0.85 to 1.16) | 0.91 | 0.20 | 0.06 |
| Angina pectoris | 1.04 (0.94 to 1.15) | 0.41 | 0.11 | 0.95 (0.80 to 1.12) | 0.51 | 0.11 | 0.15 |
| Atrial fibrillation and flutter | 1.01 (0.91 to 1.12) | 0.87 | 0.05 | 0.90 (0.75 to 1.08) | 0.23 | 0.07 | 0.41 |
| Circulatory disease | 1.04 (1.00 to 1.09) | 0.08 | 0.40 | 0.97 (0.89 to 1.07) | 0.57 | 0.05 | 0.26 |
| Varicose veins of lower extremity | 0.86 (0.72 to 1.02) | 0.09 | 0.55 | 0.86 (0.67 to 1.10) | 0.24 | 0.97 | 0.55 |
| Disorders of iron metabolism | 1.19 (0.74 to 1.90) | 0.45 | 0.11 | 0.79 (0.15 to 4.07) | 0.77 | 0.47 | 0.12 |
| Hypercholesterolaemia | 1.14 (0.96 to 1.36) | 0.12 | 0.94 | 1.18 (0.88 to 1.58) | 0.27 | 0.78 | 0.99 |
| Hypothyroidism | 1.10 (0.99 to 1.23) | 0.07 | 0.39 | 0.99 (0.75 to 1.32) | 0.97 | 0.30 | 0.05 |
| Disorders of thyroid | 1.08 (0.98 to 1.20) | 0.10 | 0.31 | 1.01 (0.79 to 1.29) | 0.94 | 0.41 | 0.05 |
| Benign neoplasm of digestive system | 0.93 (0.78 to 1.10) | 0.36 | 0.11 | 0.90 (0.64 to 1.26) | 0.52 | 0.79 | 0.18 |
| Gastritis and duodenitis | 0.97 (0.88 to 1.07) | 0.53 | 0.09 | 0.95 (0.80 to 1.13) | 0.55 | 0.70 | 0.16 |
| Nasal polyps | 1.08 (0.88 to 1.34) | 0.45 | 0.10 | 1.09 (0.73 to 1.60) | 0.67 | 0.98 | 0.12 |
| Cataract | 0.99 (0.90 to 1.09) | 0.85 | 0.05 | 0.91 (0.75 to 1.10) | 0.34 | 0.23 | 0.36 |
| Poisoning by antibiotics | 0.85 (0.70 to 1.04) | 0.14 | 0.25 | 1.00 (0.68 to 1.48) | 1.00 | 0.28 | 0.05 |
| Complications of labour and delivery† | 0.89 (0.76 to 1.03) | 0.12 | 0.30 | 0.78 (0.59 to 1.02) | 0.08 | 0.20 | 0.83 |
| Other diseases of respiratory system† | 1.11 (0.94 to 1.31) | 0.19 | 0.22 | 1.16 (0.92 to 1.46) | 0.22 | 0.64 | 0.42 |
| Disorder of skin and subcutaneous tissue† | 0.99 (0.93 to 1.06) | 0.77 | 0.06 | 0.98 (0.89 to 1.09) | 0.75 | 0.85 | 0.09 |
*The statistical power of MR analyses was calculated by using the non-centrality parameter-based approach65; the overall proportion of variance (R2) of serum uric acid level explained by the genetic instruments was estimated to be 7.0%.25
†Disease outcomes identified from sex-stratified PheWAS analysis.
IVW, inverse-variance weighted; MR, Mendelian randomisation; PheWAS, phenome-wide association study.